Neurocrine drops MS agent
This article was originally published in Pharmaceutical Approvals Monthly
Neurocrine Biosciences discontinues NBI-5788 compound development for multiple sclerosis following the altered peptide ligand (APL) product's Phase II failure, the firm announces March 8. "The company will complete its other APL Phase II study, which is evaluating the APL technology for the treatment of type 1 diabetes, which is utilizing a different APL epitope," Neurocrine says. The Phase II MS trial failed to show statistical significance in 157 subjects over a nine-month period….
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.